Back to Search Start Over

Teclistamab as an Effective Treatment for Pericardial Effusion in Relapsed Multiple Myeloma: Case Report and a Brief Literature Review

Authors :
Sai Samyuktha Bandaru
Naveen Singh Multani
William Thomas Nauam
Cibar Benitez-Ferina
Source :
Case Reports in Oncology, Vol 17, Iss 1, Pp 1063-1069 (2024)
Publication Year :
2024
Publisher :
Karger Publishers, 2024.

Abstract

Introduction: Multiple myeloma represents a malignant disorder of plasma cells. Extramedullary relapse in multiple myeloma is a rare occurrence, and pericardial involvement stands as an exceedingly uncommon manifestation. Only a few documented cases of pericardial effusion as an extramedullary relapse presentation of myeloma exist. Bispecific antibodies are emerging as a novel class of immunotherapy drugs for the treatment of relapsed refractory multiple myeloma patients who have experienced failure with four prior lines of therapy. According to a literature review, none of the reported cases with pericardial effusion relapsed myeloma have been treated with bispecific antibodies, given that these drugs have only recently gained approval. Case Presentation: We present a rare case of a patient with pericardial effusion resulting from myeloma relapse, treated with teclistamab, a bispecific antibody, and achieving an excellent response. Conclusion: Bispecific antibodies, such as teclistamab, show great effectiveness as a treatment for patients with relapsed refractory multiple myeloma, including those with extramedullary disease.

Details

Language :
English
ISSN :
16626575, 00054097, and 44352999
Volume :
17
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Case Reports in Oncology
Publication Type :
Academic Journal
Accession number :
edsdoj.74a44352999c464fb6f1d6ca9e4c069f
Document Type :
article
Full Text :
https://doi.org/10.1159/000540979